What do systematic reviews say?

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1132 participants
  Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 946 participants
  Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 944 participants
  Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 944 participants
  Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1057 participants
  Moderate

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 506 participants
  Moderate

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

It is very uncertain whether homeopathic medicinal products (non‐individualised treatment) changes adverse events compared with placebo or usual care (very low certainty).

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  OR 0.26 [0.03, 2.43]
  1 study · 95 participants
  Very low

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

The review found no eligible studies for this question.

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

Homeopathic medicinal products (non‐individualised treatment) showed no clear difference in recurrence of ARTI compared with placebo or usual care (low certainty).

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  OR 0.6 [0.21, 1.72]
  3 studies · 735 participants
  Low

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

The review found no eligible studies for this question.

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

The review found no eligible studies for this question.

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions directed at individuals: full financial coverage vs no financial coverage

Interventions directed at individuals: full financial coverage probably leads to higher abstinence from smoking compared with no financial coverage (moderate certainty).

• Healthcare financing systems for increasing the use of tobacco dependence treatment 2017 · Cochrane Headline outcomes only
  RR 1.77 [1.37, 2.28]
  6 studies · 9333 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1061 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1139 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1134 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1134 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  High